(Table 9
Clinical evidence and mechanisms of high-protein diet-induced weight loss
For more on this peptide, see our BPC-157 profile, BPC-157 side effects guide, BPC-157 before and after results, and BPC-157 and alcohol interactions
BPC-157, or Body Protecting Compound-157, is a 15-amino-acid peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) isolated from gastric juices.[1][2] It was first identified in the 1990s as part of research into cytoprotective agents that safeguard the gastrointestinal (GI) tract from damage.[3] Unlike many peptides, BPC-157 is highly stable in acidic environments, allowing for oral administration without significant degradation.[4] In compounding pharmacies, BPC-157 is often prepared as capsules, injectables, or topical formulations
(2018) 115:E29609
HONG KONG CHOICES Hong Kong's Mandatory Provident Fund investors who are interested in these drug giants can opt for Manulife's MPF Healthcare Fund, which holds an 8.4 percent stake in Eli Lilly, its largest holding, and 6.04 percent stake in Novo Nordisk